1-5 of 5
Monica Red Brewer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca Nagy, Richard Lanman, Michael F. Berger, David M. Hyman, David B. Solit, Jie He, Vincent Miller, Richard E. Cutler, Jr, Alshad S. Lalani, Darren Cross, Christine M. Lovly, Jens Meiler, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2019) 9 (2): 303.
https://doi.org/10.1158/2159-8290.CD-18-1515
Published: 08 February 2019
View article titled, Correction: An Acquired <em>HER2</em><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Open the PDF for Correction: An Acquired <em>HER2</em><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer in another window
Journal Articles

An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca Nagy, Richard Lanman, Michael F. Berger, David M. Hyman, David B. Solit, Jie He, Vincent Miller, Richard E. Cutler, Jr, Alshad S. Lalani, Darren Cross, Christine M. Lovly, Jens Meiler, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2017) 7 (6): 575–585.
https://doi.org/10.1158/2159-8290.CD-16-1431
Published: 01 June 2017
View article titled, An Acquired <em>HER2</em> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Open the PDF for An Acquired <em>HER2</em> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer in another window
Includes: Supplementary data
Journal Articles

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

Jean-Nicolas Gallant, Jonathan H. Sheehan, Timothy M. Shaver, Mark Bailey, Doron Lipson, Raghu Chandramohan, Monica Red Brewer, Sally J. York, Mark G. Kris, Jennifer A. Pietenpol, Marc Ladanyi, Vincent A. Miller, Siraj M. Ali, Jens Meiler, Christine M. Lovly
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2015) 5 (11): 1155–1163.
https://doi.org/10.1158/2159-8290.CD-15-0654
Published: 01 November 2015
View article titled, <em>EGFR</em> Kinase Domain Duplication (<em>EGFR</em>-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib
Open the PDF for <em>EGFR</em> Kinase Domain Duplication (<em>EGFR</em>-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib in another window
Includes: Supplementary data
Journal Articles

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan E. Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay, Richard A. Ward, Martine J. Mellor, Gareth Hughes, Amar Rahi, Vivien N. Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H.P. Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R. Ranson, William Pao
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2014) 4 (9): 1046–1061.
https://doi.org/10.1158/2159-8290.CD-14-0337
Published: 01 September 2014
View article titled, AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Open the PDF for AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Maximizing the Benefits of Off-Target Kinase Inhibitor Activity

Monica Red Brewer, William Pao
Journal: Cancer Discovery
Cancer Discov (2013) 3 (2): 138–140.
https://doi.org/10.1158/2159-8290.CD-12-0581
Published: 10 February 2013
View article titled, Maximizing the Benefits of Off-Target Kinase Inhibitor Activity
Open the PDF for Maximizing the Benefits of Off-Target Kinase Inhibitor Activity in another window